Advancing ASO therapies from development to implementation

Nature Medicine, vol. 30, pp. 2725–2726

Authors 4

1. Rebecca Schüle

   Heidelberg University · University Hospital Heidelberg · Hertie Institute for Clinical Brain Research · University of Tübingen

   Affiliation as printed

   Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

   Division of Neurodegenerative Diseases, Department of Neurology, Heidelberg University Hospital and Faculty of Medicine, Heidelberg, Germany

2. Matthis Synofzik

   German Center for Neurodegenerative Diseases · Hertie Institute for Clinical Brain Research · University of Tübingen

   Affiliation as printed

   Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

   German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany

3. Holm Graeßner

   University of Tübingen

   Affiliation as printed

   Centre for Rare Diseases and Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

4. Annemieke M Aartsma-Rus corresponding Aachen Department of Human Genetics

   Leiden University Medical Center

   Affiliation as printed

   Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. a.m.rus@lumc.nl